- Home
- EPM vs VTVT Comparison
EPM vs VTVT Comparison
Compare EPM & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPM | VTVT |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.2M | 143.7M |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EPM | VTVT |
|---|---|---|
| Price | $4.49 | $35.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.93 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 412.9K | 44.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $43,229,621.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $92.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.19 | $14.00 |
| 52 Week High | $5.70 | $44.00 |
Technical Indicators
Market Signals| Indicator | EPM | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 53.70 | 51.40 |
| Support Level | $4.38 | $31.42 |
| Resistance Level | $4.63 | $42.71 |
| Average True Range (ATR) | 0.16 | 3.77 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 37.17 | 61.66 |
Price Performance
Historical ComparisonAbout EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.